Literature DB >> 1424868

Role of chronic Pseudomonas aeruginosa infection in the development of bronchiectasis.

M Nagaki1, S Shimura, Y Tanno, T Ishibashi, H Sasaki, T Takishima.   

Abstract

To understand the role of Pseudomonas aeruginosa infection in the development of bronchiectasis, we investigated by CT the presence of bronchiectasis in two groups of chronic bronchitis patients and in a control group. There were no differences in clinical or laboratory findings between groups A and B. Three observers without any knowledge of these patients reported bronchiectasis on a scale of 0 to 3 and bronchial wall thickness on a scale of 0 to 3 in each lobe of both lungs. Bronchiectasis and wall thickness scores in group A (chronic bronchitis with P aeruginosa infection) were significantly higher than bronchiectasis scores and wall thickness in group B (chronic bronchitis without P aeruginosa infection). Both scores in group B were higher than those in group C (control group). These findings support the idea that chronic P aeruginosa infection plays a role in the development of bronchiectasis.

Entities:  

Mesh:

Year:  1992        PMID: 1424868     DOI: 10.1378/chest.102.5.1464

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Genome macrorestriction analysis of sequential Pseudomonas aeruginosa isolates from bronchiectasis patients without cystic fibrosis.

Authors:  S W Hla; K P Hui; W C Tan; B Ho
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

2.  Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.

Authors:  María D Maciá; David Blanquer; Bernat Togores; Jaume Sauleda; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; María D Maciá; Olivia Gutiérrez; Carmen Vidal; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study.

Authors:  K A Miszkiel; A U Wells; M B Rubens; P J Cole; D M Hansell
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

5.  Virtual screening of AmpC/β-lactamase as target for antimicrobial resistance in Pseudomonas aeruginosa.

Authors:  Rohit Farmer; Budhayash Gautam; Satendra Singh; Pramod Kumar Yadav; Prashant Ankur Jain
Journal:  Bioinformation       Date:  2010-01-17

6.  Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.

Authors:  M D Maciá; N Borrell; M Segura; C Gómez; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection.

Authors:  T Fujii; J Kadota; K Kawakami; K Iida; R Shirai; M Kaseda; S Kawamoto; S Kohno
Journal:  Thorax       Date:  1995-12       Impact factor: 9.139

8.  Epidemiological analysis of sequential Pseudomonas aeruginosa isolates from chronic bronchiectasis patients without cystic fibrosis.

Authors:  I Pujana; L Gallego; G Martín; F López; J Canduela; R Cisterna
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

9.  Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators.

Authors:  Adela M Luján; María D Maciá; Liang Yang; Søren Molin; Antonio Oliver; Andrea M Smania
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

10.  The development of selective inhibitors of NagZ: increased susceptibility of Gram-negative bacteria to β-lactams.

Authors:  Keith A Stubbs; John-Paul Bacik; G Evan Perley-Robertson; Garrett E Whitworth; Tracey M Gloster; David J Vocadlo; Brian L Mark
Journal:  Chembiochem       Date:  2013-09-05       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.